在抗PD-1 治疗后,Replimune 的试验显示了RP1 和尼沃卢马布在黑色素瘤患者中的有希望的结果. Replimune's trial shows promising results for RP1 and nivolumab in melanoma patients post anti-PD-1.

康复小组分享了其IGNYTE在SITC 2024年临床试验的结果,测试了以前未能进行抗PD-1治疗的黑皮瘤病人的RP1和Nivolumab的结合情况。 Replimune Group shared findings from its IGNYTE clinical trial at the SITC 2024, testing the combination of RP1 and nivolumab in melanoma patients who previously failed anti-PD-1 therapy. 试验显示,总体答复率为33.6%,中位答复期为21.6个月。 The trial showed a 33.6% overall response rate, with a median response duration of 21.6 months. 反应者中的大多数损伤在体积上显著下降,初步生物标志数据表明免疫反应强烈。 Most lesions in responders decreased in size significantly, and initial biomarker data indicated a strong immune response. 存活率显著,一年的存活率为75.3%。 Survival rates were notable, with 75.3% at one year.